American Society of Hematology Annual Meeting 2024 – Updates in Myelofibrosis (Part 2)

Dr. Angela Fleischman and Dr. Gabriella Hobbs discussed two intriguing abstracts presented at the ASH 2024 Annual Meeting about emerging treatments for myelofibrosis. The first study, led by Dr. Lucia Massarova, explored the safety and preliminary efficacy of cord blood-derived CXCR4-enriched T-regulatory cells in patients with suboptimal response to ruxolitinib, showing minimal adverse events and potential improvements in hemoglobin, spleen size, and symptoms. The second study evaluated nuvusertib (TP3654), a selective PIM1 kinase inhibitor, in patients with relapsed/refractory myelofibrosis, demonstrating stable hemoglobin and platelet levels, symptom and spleen volume improvement, and preliminary evidence of fibrosis and cytokine response.